ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies

BACKGROUND: ATP13A2 (PARK9) loss of function mutations are a genetic cause of an early-onset form of Parkinson’s disease (PD), with in vitro studies showing that ATP13A2 deficits lead to lysosomal and mitochondrial dysfunction and α-synuclein accumulation, while elevated ATP13A2 expression reduces α...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Karen E, Cottle, Louise, Gysbers, Amanda M, Cooper, Antony A, Halliday, Glenda M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046687/
https://www.ncbi.nlm.nih.gov/pubmed/24252509
http://dx.doi.org/10.1186/2051-5960-1-11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046687/
https://www.ncbi.nlm.nih.gov/pubmed/24252509
http://dx.doi.org/10.1186/2051-5960-1-11

Ejemplares similares